VivoSeq
Dermatology

Actinic Keratosis

57

Pipeline Programs↗

11

Active Trials↗

29

Companies Involved↗

Actinic Keratosis is a moderately active landscape with 57 programs across 29 companies. The most active players are Metro International Biotech, LLC, Kinex Pharmaceuticals Inc., Promius Pharma, LLC. 12 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

25/100

Mech. Concentration

14/100

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Metro International Biotech, LLC

1 program

Phase 1K

Kinex Pharmaceuticals Inc.

1 program

Phase 1P

Promius Pharma, LLC

6 programs

Phase 2H

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

1 program

Phase 2S

Spirig Pharma Ltd.

1 program

Phase 2V

Validus Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

99%

Small molecule

94 of 95 classified programs — the dominant modality here.

1%ALL OTHERSVaccine11%

Small molecule leads; the ring shows all 95 classified programs, each share of the total. Modality classified for 100% of 96 pipeline programs.

Analysis

Trial Status

127

clinical trials

Completed105 · 83%
Unknown status7 · 6%
Recruiting5 · 4%
Active, not recruiting4 · 3%
Terminated3 · 2%
Not yet recruiting2 · 2%
Other1 · 1%

Clinical Trials

Trial Activity

127 trials

Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis
Recruiting·AAresus Pharma GmbH·Phase 3·NCT07137819·280 enrolled
Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis
Recruiting·MMaastricht University Medical Center·Phase 4·NCT06499415·232 enrolled
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
Recruiting·PPsoriasis Treatment Center of Central New Jersey·Phase 4·NCT06745999·40 enrolled
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Recruiting·HHubei Bio-Pharmaceutical Industrial Technological Institute Inc.·Phase 1·NCT07318675·40 enrolled
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
Recruiting·RRubedo Life Sciences, Inc.·Phase 1/2·NCT07340697·24 enrolled
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Active, not recruiting·Sun Pharmaceutical Industries, Inc. logoSun Pharmaceutical Industries, Inc.·Phase 3·NCT07144852·260 enrolled
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
Active, not recruiting·—·Phase 4·NCT05387525·447 enrolled
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Active, not recruiting·Sun Pharmaceutical Industries, Inc. logoSun Pharmaceutical Industries, Inc.·Phase 3·NCT07144345·160 enrolled
Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis
Active, not recruiting·—·Phase 2·NCT05202860·70 enrolled
Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead
Not yet recruiting·UUniversity Hospital, Lille·Phase 3·NCT07273656·59 enrolled
A Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HW211026 Ointment in Patients With Actinic Keratosis.
Not yet recruiting·HHubei Bio-Pharmaceutical Industrial Technological Institute Inc.·Phase 2·NCT07513454·80 enrolled
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
Completed·—·Phase 3·NCT03285490·351 enrolled
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
Completed·LEO Pharma logoLEO Pharma·Phase 1·NCT02124239·79 enrolled
Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis
Completed·—·Phase 1·NCT02670655·45 enrolled
Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis
Completed·LEO Pharma logoLEO Pharma·Phase 1·NCT01703078·41 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)